Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)

Further Publications

Prognostic significance of pleural fluid microbiological positivity in pleural infection: a bicentric 10-year retrospective observational study

Respir Res

Wong C, Fan HC, Rahman NM, Wong JCC, Cheng HS, Chiu PH, Tong CW, Miu FPL, Yam LYC

doi: 10.1186/s12931-025-03129-5

RECOMMENDED

Asthma

Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir J

Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE

doi: 10.1183/13993003.00316-2024

RECOMMENDED

Lung Cancer

Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections

★ 1 Recommended by Dr Martin Frey, Faculty Member

Clin Lung Cancer

Somisetty M, Mack PC, Hsu CY, Huang Y, Gomez JE, Rodilla AM, Cagan J, Tavolacci SC, Carreño JM, Brody R, Moore AC, King JC, Rohs NC, Rolfo C, Bunn PA, Minna JD, Bhalla S, Krammer F, García-Sastre A, Figueiredo JC, Kazemian E, Reckamp KL, Merchant AA, Nadri M, Ahmed R, Ramalingam SS, Shyr Y, Hirsch FR, Gerber DE

doi: 10.1016/j.cllc.2024.07.007

RECOMMENDED

Lung Cancer

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C, GFPC 08–2015 ENERGY investigators

doi: 10.1016/S2213-2600(24)00264-9

Asthma

Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

Adv Ther

Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B

doi: 10.1007/s12325-025-03231-6

RECOMMENDED

COPD

Use of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitor is Associated with reduced Emergency Room Visits and Hospitalization in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Diabetes Mellitus

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Shanmugavel Geetha H, Teo YX, Ravichandran S, Perkitt NR, Gogtay M, Lal A, Abraham GM, Trivedi N

doi: 10.1016/j.rmed.2024.107819

Asthma

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Initiation in Japanese Patients with Asthma Previously on Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: A Retrospective Cohort Study

J Clin Med

Oga T, Gon Y, Takano M, Ito R, Mita C, Mukai I, Noorduyn SG, Requena G, Yarita M

doi: 10.3390/jcm14082566

RECOMMENDED

Pleural DiseasesFurther Publications

Mortality after treatment of malignant pleural effusions with indwelling pleural catheters versus chemical pleurodesis: a population-based study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Kwok C, Thavorn K, Amjadi K, Aaron SD, Kendzerska T

doi: 10.1186/s12931-024-03023-6

Lung Cancer

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)

Clin Lung Cancer

Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM

doi: 10.1016/j.cllc.2025.05.014

Related content

Prognostic significance of pleural fluid microbiological positivity in pleural infection: a bicentric 10-year retrospective observational study

Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study

Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

Use of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitor is Associated with reduced Emergency Room Visits and Hospitalization in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Diabetes Mellitus

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Initiation in Japanese Patients with Asthma Previously on Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: A Retrospective Cohort Study

Mortality after treatment of malignant pleural effusions with indwelling pleural catheters versus chemical pleurodesis: a population-based study

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)